Hannah F. J. Shapiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hannah F. J. Shapiro has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa Lebel
Division of Pain Medicine, Department of Anesthesiology, Critical Care & Pain Medicine, Boston Children’s Hospital, Boston, MA 02115, USA
1 shared publication - Amy A. Gelfand
Department of Neurology, Child & Adolescent Headache Program, University of California San Francisco, San Francisco, CA, USA
1 shared publication Anna Minster
Department of Neurology, Boston Children's Hospital, Boston, Massachusetts
1 shared publicationChen Chen
Scripps Institution of Oceanography University of California San Diego La Jolla California USA
1 shared publicationDaniel J. Shapiro
Department of Emergency Medicine University of California, San Francisco San Francisco California USA
1 shared publication- Daniel J. Shapiro
Division of Pediatric Emergency Medicine, University of California, San Francisco
1 shared publication
Latest Publications
- 24 January 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (4) , 791-792
Comfort matters: A new strategy to ease injection pain during headache treatment procedures
- 24 January 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (4) , 791-792
Comfort matters: A new strategy to ease injection pain during headache treatment procedures
- Open Access
- 26 September 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (5) , 1058-1068
Association between wildfire smoke exposure and pediatric emergency department visits for headache
Objective: The purpose of this study was to determine whether short‐term exposure to wildfire smoke is associated with emergency department visits for headache in children and adolescents. Background: Wildfires are becoming increasingly common and are associated with numerous adverse health outcomes. However, we currently do not know how wildfire smoke exposure affects children and adolescents with primary headache disorders. Headache disorders in youth are a major contributor to frequently missed school days and youth with headache disorders have high medical care utilization and total healthcare costs. Therefore, understanding factors that may contribute to headache exacerbations and potential increases in healthcare utilization is of particular interest. Methods: This was a time‐stratified case‐crossover study linking daily health data from the California Department of Health Care Access and Information to daily ZIP code‐level wildfire PM 2.5 concentrations between 2006 and 2019. We included all visits for headache to emergency departments in California among youth 5–19 years old during the study period. The primary exposure was the ZIP code‐level daily wildfire‐specific PM 2.5 concentration, modeled as a continuous and binary (wildfire‐specific PM 2.5 ≥15 μg/m 3 ) variable. The primary outcome was an emergency department visit for headache. We identified relevant encounters according to the International Classification of Diseases, 9th/10th revision codes assigned in the first diagnostic position. To capture a potential delayed impact, we estimated odds ratios for the association for days 0 to 6 between the exposure and outcome. Results: We identified 206,230 unique emergency department encounters for primary headache disorders. Most visits were in female patients (61.4%) 15–19 years old (58.5%) who identified as Hispanic (48.8%) and lived in a very low‐opportunity (37.7%) or low‐opportunity (21.6%) neighborhood. The adjusted odds of an emergency department visit incrementally decreased per unit increase in wildfire‐specific PM 2.5 concentrations from days 0 to 6 after wildfire smoke exposure (same‐day adjusted odds ratio [aOR], 1.00; 95% confidence interval [CI], 0.998–1.001; day +6 aOR, 0.995; 95% CI, 0.993–0.997). Using a binary exposure, the adjusted odds of an emergency department visit incrementally decreased from days 0 to 6 after a wildfire smoke day (same day aOR, 0.99; 95% CI, 0.92–1.08; day +6 aOR, 0.84; 95% CI, 0.78–0.92). Conclusion: Children are less likely to seek care in the emergency department for primary headache in the days following exposure to wildfire smoke, suggesting that healthcare utilization changes during wildfires. Clinicians should ensure youth with headache disorders who experience worsening symptoms associated with air pollution are equipped with strategies to manage their headache disorder at home during days with wildfire smoke, including effective at‐home acute headache medications.
- 26 September 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (5) , 1058-1068
Open AccessAssociation between wildfire smoke exposure and pediatric emergency department visits for headache
Objective: The purpose of this study was to determine whether short‐term exposure to wildfire smoke is associated with emergency department visits for headache in children and adolescents. Background: Wildfires are becoming increasingly common and are associated with numerous adverse health outcomes. However, we currently do not know how wildfire smoke exposure affects children and adolescents with primary headache disorders. Headache disorders in youth are a major contributor to frequently missed school days and youth with headache disorders have high medical care utilization and total healthcare costs. Therefore, understanding factors that may contribute to headache exacerbations and potential increases in healthcare utilization is of particular interest. Methods: This was a time‐stratified case‐crossover study linking daily health data from the California Department of Health Care Access and Information to daily ZIP code‐level wildfire PM 2.5 concentrations between 2006 and 2019. We included all visits for headache to emergency departments in California among youth 5–19 years old during the study period. The primary exposure was the ZIP code‐level daily wildfire‐specific PM 2.5 concentration, modeled as a continuous and binary (wildfire‐specific PM 2.5 ≥15 μg/m 3 ) variable. The primary outcome was an emergency department visit for headache. We identified relevant encounters according to the International Classification of Diseases, 9th/10th revision codes assigned in the first diagnostic position. To capture a potential delayed impact, we estimated odds ratios for the association for days 0 to 6 between the exposure and outcome. Results: We identified 206,230 unique emergency department encounters for primary headache disorders. Most visits were in female patients (61.4%) 15–19 years old (58.5%) who identified as Hispanic (48.8%) and lived in a very low‐opportunity (37.7%) or low‐opportunity (21.6%) neighborhood. The adjusted odds of an emergency department visit incrementally decreased per unit increase in wildfire‐specific PM 2.5 concentrations from days 0 to 6 after wildfire smoke exposure (same‐day adjusted odds ratio [aOR], 1.00; 95% confidence interval [CI], 0.998–1.001; day +6 aOR, 0.995; 95% CI, 0.993–0.997). Using a binary exposure, the adjusted odds of an emergency department visit incrementally decreased from days 0 to 6 after a wildfire smoke day (same day aOR, 0.99; 95% CI, 0.92–1.08; day +6 aOR, 0.84; 95% CI, 0.78–0.92). Conclusion: Children are less likely to seek care in the emergency department for primary headache in the days following exposure to wildfire smoke, suggesting that healthcare utilization changes during wildfires. Clinicians should ensure youth with headache disorders who experience worsening symptoms associated with air pollution are equipped with strategies to manage their headache disorder at home during days with wildfire smoke, including effective at‐home acute headache medications.
- Open Access
- 11 September 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (9) , 1232-1239
Association between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study
Objective: We aimed to compare the prescribing patterns of preventive medications between pediatric and adult neurologists for young adults with migraine.Background: Although preventive medications are effective for adults with migraine, studies in children have failed to demonstrate similar efficacy. As a result, lifestyle modifications and non‐pharmacological interventions are often emphasized in children. It is not known whether young adults are prescribed preventive medications at different rates according to whether they are cared for by an adult or pediatric neurologist.Methods: We performed a multicenter retrospective cohort analysis of patients with migraine aged 18–25 years who were seen by a pediatric or adult neurologist at Mass General Brigham Hospital between 2017 and 2021. The primary outcome was whether the patient received a prescription for any preventive medication during the study period.Results: Among the 767 included patients, 290 (37.8%) were seen by a pediatric neurologist. Preventive medications were prescribed for 131/290 (45.2%; 95% confidence interval [CI]: 39.5%, 51.0%) patients seen by a pediatric neurologist and 206/477 (43.2%; 95% CI: 39.0%, 47.7%) patients seen by an adult neurologist (p = 0.591). In the mixed effects logistic regression model, clinician specialty was not associated with preventive medication use (adjusted odds ratio [AOR] 1.20, 95% CI: 0.62, 2.31). Female sex (AOR 1.69, 95% CI: 1.07, 2.66) and number of visits during the study period (AOR 1.64, 95% CI: 1.49, 1.80) were associated with receiving preventive medication.Conclusion: Approximately two fifths of young adults with migraine were prescribed preventive medications, and this proportion did not differ according to clinician specialty. Although these findings suggest that pediatric and adult neurologists provide comparable care, both specialties may be underusing preventive medications in this patient population.
- 11 September 2023
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 63 (9) , 1232-1239
Open AccessAssociation between clinician specialty and prescription of preventive medication for young adults with migraine: A retrospective cohort study
Objective: We aimed to compare the prescribing patterns of preventive medications between pediatric and adult neurologists for young adults with migraine.Background: Although preventive medications are effective for adults with migraine, studies in children have failed to demonstrate similar efficacy. As a result, lifestyle modifications and non‐pharmacological interventions are often emphasized in children. It is not known whether young adults are prescribed preventive medications at different rates according to whether they are cared for by an adult or pediatric neurologist.Methods: We performed a multicenter retrospective cohort analysis of patients with migraine aged 18–25 years who were seen by a pediatric or adult neurologist at Mass General Brigham Hospital between 2017 and 2021. The primary outcome was whether the patient received a prescription for any preventive medication during the study period.Results: Among the 767 included patients, 290 (37.8%) were seen by a pediatric neurologist. Preventive medications were prescribed for 131/290 (45.2%; 95% confidence interval [CI]: 39.5%, 51.0%) patients seen by a pediatric neurologist and 206/477 (43.2%; 95% CI: 39.0%, 47.7%) patients seen by an adult neurologist (p = 0.591). In the mixed effects logistic regression model, clinician specialty was not associated with preventive medication use (adjusted odds ratio [AOR] 1.20, 95% CI: 0.62, 2.31). Female sex (AOR 1.69, 95% CI: 1.07, 2.66) and number of visits during the study period (AOR 1.64, 95% CI: 1.49, 1.80) were associated with receiving preventive medication.Conclusion: Approximately two fifths of young adults with migraine were prescribed preventive medications, and this proportion did not differ according to clinician specialty. Although these findings suggest that pediatric and adult neurologists provide comparable care, both specialties may be underusing preventive medications in this patient population.
- Open Access
- 1 February 2022
- Published by Elsevier in Pediatric Neurology
- Vol. 127, 41-47
Development and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache
- 1 February 2022
- Published by Elsevier in Pediatric Neurology
- Vol. 127, 41-47
Open AccessDevelopment and Evaluation of an Integrated Outpatient Infusion Care Model for the Treatment of Pediatric Headache
- Open Access
Pediatric Episodic Migraine with Aura: A Unique Entity?
Migraine headache is a common cause of pain and disability in children and adolescents and is a major contributor to frequently missed school days and limitations in activities. Of children and adolescents with migraine headache, approximately one-third have migraine with aura (MA). MA is often considered to be similar to migraine without aura (MO), and thus, many studies do not stratify patients based on the presence of aura. Because of this, treatment recommendations are often analogous between MA and MO, with a few notable exceptions. The purpose of this review is to highlight the current evidence demonstrating the unique pathophysiology, clinical characteristics, differential diagnosis, co-morbidities, and treatment recommendations and responses for pediatric MA.
Open AccessPediatric Episodic Migraine with Aura: A Unique Entity?
Migraine headache is a common cause of pain and disability in children and adolescents and is a major contributor to frequently missed school days and limitations in activities. Of children and adolescents with migraine headache, approximately one-third have migraine with aura (MA). MA is often considered to be similar to migraine without aura (MO), and thus, many studies do not stratify patients based on the presence of aura. Because of this, treatment recommendations are often analogous between MA and MO, with a few notable exceptions. The purpose of this review is to highlight the current evidence demonstrating the unique pathophysiology, clinical characteristics, differential diagnosis, co-morbidities, and treatment recommendations and responses for pediatric MA.